looks as though Eli Lilly is also keen to develop a glucose-sensitive insulin that 'does away with the need for constant monitoring and multiple daily injections' as it has just announced the acquisition of privately held Protomer which is designing the linker...
-
Please Remember: Members are only permitted to share their own experiences. Members are not qualified to give medical advice. Additionally, everyone manages their health differently. Please be respectful of other people's opinions about their own diabetes management.
-
Learn more about joining the Diabetes UK Support Forum team here: https://forum.diabetes.org.uk/boards/threads/volunteering-opportunities-why-dont-you-join-us.112862/
Novo Nordisk Buys British ‘Smart’ Insulin Diabetes Biotech in deal worth €702M
- Thread starter Northerner
- Start date
-
- Tags
- smart insulin
- Status
interesting graphs,could you explain them,presumably the second graph relates to NN's glucose sensitive insulin?
Novo third quarter report- NN1845 safe and well tolerated in phase 1 demonstrating proof of principle for a glucose sensitive insulin, further work to optimise pharmacokinetic properties, programme continuing....does this indicate the present formulation is not sufficiently rapid in one or all of onset,durability or in switching off at low glucose concentrations?
Last edited:
just been watching novo nordisk's 2022 capital markets day r and d presentation powerpoint, which was held today.
seems the glucose sensitive insulin project NN1845 or NN845 is ongoing through the rest of 2022 in phase 1, looks to me that the pharmacokinetics are troublesome, over longevity of its action in the circulation though they are claiming proof of concept? so the whole formulation may need to be tweaked or the project abandoned,
will try to listen in to the other parts of the day's presentations, seems there are multiple other projects of interest ongoing particularly in the type 2 field. Anyone interested can gain access through the novo nordisk.com website....
seems the glucose sensitive insulin project NN1845 or NN845 is ongoing through the rest of 2022 in phase 1, looks to me that the pharmacokinetics are troublesome, over longevity of its action in the circulation though they are claiming proof of concept? so the whole formulation may need to be tweaked or the project abandoned,
will try to listen in to the other parts of the day's presentations, seems there are multiple other projects of interest ongoing particularly in the type 2 field. Anyone interested can gain access through the novo nordisk.com website....
- Relationship to Diabetes
- Type 1
- Pronouns
- He/Him
It was always going to be a very tricky nut to crack.
3 or 4 years down the line I guess there will come a time where they will have to decide whether or not the work done so far still has legs.
3 or 4 years down the line I guess there will come a time where they will have to decide whether or not the work done so far still has legs.
correction
they're claiming proof of principle for the glucose sensitive insulin NN1845/ NN845 which is less strenuous as a test than proof of concept which has yet to be determined by the looks of it but verdict will be reached by the end of this year on the latter, not altogether encouraging -think the most likely problem is duration of action in the circulation,
they have the ziylo programme possibly to fall back on though that may suffer from the same problem of response duration.
they're claiming proof of principle for the glucose sensitive insulin NN1845/ NN845 which is less strenuous as a test than proof of concept which has yet to be determined by the looks of it but verdict will be reached by the end of this year on the latter, not altogether encouraging -think the most likely problem is duration of action in the circulation,
they have the ziylo programme possibly to fall back on though that may suffer from the same problem of response duration.
seems that Novo did a second phase 1 study on their candidate smart insulin NN1845 in 30 subjects in Graz Austria.
the control comparison was, surprisingly, levemir suggesting that the smart insulin is not particularly fast-responding and might therefore only represent a better basal insulin rather than a replacement for Fiasp or rapid-acting insulins? Also, the trial involves 6 hourly injections suggesting that durability in the circulation is not great. Results may be announced August 4 or by the end of the year.
the control comparison was, surprisingly, levemir suggesting that the smart insulin is not particularly fast-responding and might therefore only represent a better basal insulin rather than a replacement for Fiasp or rapid-acting insulins? Also, the trial involves 6 hourly injections suggesting that durability in the circulation is not great. Results may be announced August 4 or by the end of the year.
- Status